Abstract B05: GSTM1 as risk factor for breast cancer: Meta-analysis of 57 studies

BACKGROUNDS: Breast cancer or breast carcinoma is the most common type of malignancy in women globally. According to the previous studies that indicate the usage of antihypertensive drugs may become a risk factor of cancer (beta-blockers [BBs], calcium channel blockers [CCBs], and diuretics). Both angiotensin-converting enzymes inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), on the other hand, have been associated to an increased or decreased risk of breast cancer. AIM: To compare each type of antihypertensive medicines as a risk factor for breast cancer, we did a systematic review and meta-analysis of current evidence. METHODS: We utilized the terms “antihypertensive”, “anti-hypertensive”, “anti-hypertensive medications”, “breast cancer”, “risk”, “case control”, and “cohort” in PubMed, ScienceDirect, and Google Scholar databases. RESULTS: Our data calculation found that the risk of antihypertensive drugs was significantly different in overall analysis (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.42–0.83, p = 0.003). Five studies with 39.503 breast cancer patients and 372.037 controls were included in the ARBs user sub-group. Our results found significant different of antihypertensive drugs among breast cancer patient (OR = 1.47, 95% CI = 1.02–2.11 p = 0.04). Our data calculation also confirmed no significant different in antihypertensive drugs among breast cancer patient (OR = 1.07, 95% CI = 0.99–1.16, p = 0.09) in diuretics user, (OR = 1.08, 95% CI = 0.99–1.18, p = 0.08) in CCBs user, (OR = 1.11, 95% CI = 0.98–1.26, p = 0.09) in BBs user, and (OR = 1.27, 95% CI = 0.64–2.50, p = 0.50) in ACEIs user. CONCLUSIONS: Although, the finding reveal that antihypertensive drugs (diuretics, CCBs, BBs, and ACEIs) in overall are significant for the risk of breast cancer and also found that ARBs have a low potential in the risk of breast cancer.

Download Full-text

Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: Methodologic Issues to Avoid Misinterpretation in the Meta-Analysis

Journal of Clinical Oncology ◽

10.1200/jco.2016.71.0715 ◽

2017 ◽

Vol 35 (8) ◽

pp. 923-923 ◽

Cited By ~ 6

Author(s):

Zahra Cheraghi ◽

Erfan Ayubi ◽

Amin Doosti-Irani

Keyword(s):

Breast Cancer ◽

Risk Factor ◽

Meta Analysis ◽

Trastuzumab Cardiotoxicity

Download Full-text

Investigating the impact of polysomy 17 in breast cancer patients with HER2 amplification through meta-analysis

Turkish Journal of Biochemistry ◽

10.1515/tjb-2018-0448 ◽

2019 ◽

Vol 44 (4) ◽

pp. 411-416

Author(s):

Ezel Ozge Tas ◽

Elif Pala ◽

Ilker Ercan ◽

Sebnem Sag

Keyword(s):

Breast Cancer ◽

Risk Factor ◽

Lymph Node ◽

Meta Analysis ◽

Tumor Grade ◽

Lymph Node Involvement ◽

Her2 Amplification ◽

Polysomy 17 ◽

Node Involvement ◽

Grade 3

Abstract Objectives Since studies regarding the effect of polysomy 17 (P17) in breast cancer cases with some specific clinical findings are few in number and are in small sample sizes, meta-analysis was implemented to exhibit the effects of P17 in patients with Human Epidermal growth factor Receptor 2 (HER2) amplification on lymph node involvement and tumor grade. Materials and methods Pubmed literature database was scanned up to June 2017 by using the keywords “polysomy 17 breast cancer” and 141 studies were accessed. Ultimately four of the reviewed papers have been found to be appropriate for examining the effect of P17 on lymph node involvement and tumor grade. Prior to meta-analysis, publication bias and heterogeneity of the studies was examined. Results Meta-analysis in the examining the effect of polysomy 17 on lymph node involvement (OR=1.708, 95% CI: 1.068–2.733), on grade [3]/[3,1] (OR=3.402, 95% CI: 1.726–6.707), on grade [3]/[3, 2] (OR=2.581, 95% CI: 0.778–8.559) and on grade [2]/[2,1] (OR=1.854, 95% CI: 0.531–6.468) was determined in those with HER2 amplification. Conclusion It was observed that in terms of lymph node involvement, P17 was a risk factor in patients and with regard to tumor grade, P17 was a risk factor when grade increased in patients with amplification.

Download Full-text

Is antibiotic use a risk factor for breast cancer? A meta-analysis

Pharmacoepidemiology and Drug Safety ◽

10.1002/pds.1986 ◽

2010 ◽

Vol 19 (11) ◽

pp. 1101-1107 ◽

Cited By ~ 20

Author(s):

Theodoros N. Sergentanis ◽

Flora Zagouri ◽

George C. Zografos

Keyword(s):

Breast Cancer ◽

Risk Factor ◽

Meta Analysis ◽

Antibiotic Use

Download Full-text

Cytoplasmic HAX1 Is an Independent Risk Factor for Breast Cancer Metastasis

Journal of Oncology ◽

10.1155/2019/6375025 ◽

2019 ◽

Vol 2019 ◽

pp. 1-13 ◽

Cited By ~ 2

Author(s):

Alicja Trebinska-Stryjewska ◽

Lukasz Szafron ◽

Alina Rembiszewska ◽

Maciej Wakula ◽

Sylwia Tabor ◽

...

Keyword(s):

Breast Cancer ◽

Risk Factor ◽

Independent Risk Factor ◽

Cancer Metastasis ◽

Meta Analysis ◽

Distant Metastases ◽

Copy Number Gain ◽

Breast Cancer Metastasis ◽

Primary Tumors ◽

Metastatic Relapse

HAX1 is an antiapoptotic factor involved in the regulation of cell migration and calcium homeostasis, overexpressed in several cancers, including breast cancer. It has been suggested that HAX1 is also implicated in metastasis. Herein we report the results of meta-analysis of HAX1 expression, based on publicly available data, which confirms its significant overexpression in breast cancer and demonstrates copy number gain and prognostic value of HAX1 overexpression for metastatic relapse in ER+ tumors. IHC analysis reported here also reveals its significant overexpression in breast cancer samples from primary tumors, indicating significantly higher HAX1 protein levels in a group of patients who developed distant metastases in a disease course. Moreover, we demonstrate that HAX1 localization is important for the prediction of metastatic relapse and that cytoplasmic but not nuclear HAX1 is an independent risk factor for breast cancer metastasis.

Download Full-text